<p>This poster was presented by Dr. Silverberg and colleagues at the 2020 American Academy of Dermatology virtual annual meeting.</p>
<p>This overview is provided by Dr. Alan Fleischer.</p>

This poster was presented by Dr. Silverberg and colleagues at the 2020 American Academy of Dermatology virtual annual meeting. This overview is provided by Dr. Alan Fleischer.

Patient-reported Outcome, or PROs, with Abrocitinib Treatment in Patients with Moderate to Severe Atopic Dermatitis

Welcome to this activity focusing on new research related to atopic dermatitis presented as posters at the 2020 virtual annual meetings of the American Academy of Dermatology and the American Academy of Allergy, Asthma, and Immunology. The posters focus on new data related to the use of advanced therapies for atopic dermatitis. Beyond discussing the methods and results of each poster, the faculty, Drs. Steven Feldman and Alan Fleischer, Jr., share their views on the implication of the trial results on clinical practice.

Share Patient-reported Outcome, or PROs, with Abrocitinib Treatment in Patients with Moderate to Severe Atopic Dermatitis

Sign up to save your podcasts

Patient-reported Outcome, or PROs, with Abrocitinib Treatment in Patients with Moderate to Severe Atopic Dermatitis

Patient-reported Outcome, or PROs, with Abrocitinib Treatment in Patients with Moderate to Severe Atopic Dermatitis

More shows like Research Developments in Atopic Dermatitis

Derms and Conditions